A carregar...
Novel Agents for the Management of Endocrine Resistant Breast Cancer
PURPOSE OF REVIEW: Most women with hormone receptor (HR)-positive, HER2-negative (HR+/HER2−) breast cancer will ultimately develop endocrine-resistant disease, either primary or acquired. This review will discuss the proposed mechanisms underlying endocrine resistance and key advances in the treatme...
Na minha lista:
| Publicado no: | Curr Breast Cancer Rep |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8210781/ https://ncbi.nlm.nih.gov/pubmed/34149988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12609-018-0298-3 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|